查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1990208

慢性腎臟病市場：2026-2032年全球市場預測（依治療方法、分期、最終用戶、產品類型及患者類型分類）

Chronic Kidney Disease Market by Therapy Type, Disease Stage, End User, Product, Patient Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，慢性腎臟病市場價值將達到 1,457.5 億美元，到 2026 年將成長至 1,547 億美元，到 2032 年將達到 2,296.4 億美元，複合年成長率為 6.70%。

主要市場統計數據
基準年 2025 1457.5億美元
預計年份：2026年 1547億美元
預測年份 2032 2296.4億美元
複合年成長率 (%) 6.70%

這是一個引人入勝且權威的概述，它將慢性腎臟病定位為一項緊迫的多學科臨床和運營優先事項，需要協調一致的戰略應對措施。

慢性腎臟病在臨床診療、醫療系統韌性和公共衛生管理等多個方面都構成了日益嚴峻的挑戰。此疾病不僅對診斷流程、長期治療、透析基礎設施和移植網路造成持續的負擔，而且與糖尿病和心血管疾病等共病密切相關。因此，從醫療設備製造商和藥品研發商到醫療服務提供者和保險公司，相關人員必須適應不斷變化的臨床標準、監管要求和患者照護模式。

對正在重塑慢性腎臟病診斷、治療和護理服務等各個領域的關鍵臨床、技術和經營模式變革進行深入分析。

慢性腎臟病治療格局正在經歷一場變革，其驅動力包括技術創新、醫療服務體系的重塑以及監管重點的轉變。診斷準確性的提高使得早期發現和風險分層成為可能，而數位健康平台和遠端監測則將臨床監測的範圍擴展到了傳統的住院和門診環境之外。同時，透析方法也不斷多樣化。血液透析設備和腹膜透析週期計的改進，以及更智慧的耗材和監測設備的引入，共同推動了這項變革，從而支持個人化的治療方案。

對近期關稅政策如何重塑 2025 年腎臟護理服務體系的供應鏈韌性、籌資策略和病人就醫途徑進行實際檢驗。

針對醫療技術和藥品進口徵收定向關稅，正在對慢性腎臟病系統內的供應鏈、籌資策略和成本結構產生連鎖反應。關稅的變化可能會改變進口透析設備、耗材和某些活性藥物成分相對於國產替代品的競爭力。因此，醫療機構和綜合醫療網路正在重新審視採購合約、庫存策略和供應商多元化策略，以確保依賴透析和移植的患者能夠持續獲得治療。

基於詳細細分的洞察揭示了治療方法、疾病進展、醫療保健服務環境、產品分類和患者人口統計如何決定臨床重點和商業策略。

要了解市場，需要詳細掌握治療方法類型、疾病進展階段、最終用戶、產品分類和患者人口統計等各個方面，因為每個細分維度都會影響不同的臨床和商業性趨勢。根據治療方法類型的不同，治療路徑也多種多樣，包括「診斷」（包括影像學檢查和臨床測試）、「透析」（涵蓋血液透析和腹膜透析）、「藥物治療」（包括降血壓藥、促紅細胞生成素促效劑，例如Darbepoetinα和重組人促紅血球生成素α、鐵補充劑和磷酸鹽粘合劑）以及移植（其術前和手術需求獨特）。每個治療領域都有其獨特的證據要求、監管考慮和採購週期。

對地緣政治、監管和醫療保健系統差異如何影響全球主要地區慢性腎臟病護理優先事項的區域性分析。

區域趨勢對慢性腎臟病治療的組織、資金籌措和交付方式產生重大影響，並塑造製造商、醫療服務提供者和支付方的策略重點。在美洲，人們越來越重視擴大醫療保健系統、集中式透析網路和家庭護理的規模，同時也努力透過支付方主導的打包支付和基於價值的醫療保健（VBC）試點計畫來控制下游成本。區域監管流程和報銷方案會影響創新醫療設備和藥品的上市時間，從供應鏈的角度來看，遵守國家法規和與經銷商建立長期合作關係通常是優先考慮的因素。

實際可行的競爭洞察突顯了研發投資、策略夥伴關係和卓越服務如何重塑腎臟護理產品和解決方案市場的領導地位。

慢性腎臟病)領域的競爭動態取決於技術實力、生產規模、監管專業知識和戰略夥伴關係關係的綜合作用。主要企業正大力投資於下一代透析機、提升患者舒適度和治療效果的耗材以及支援遠端患者管理的監測設備的研發。同樣重要的是醫療設備製造商、製藥公司和數位醫療服務提供者之間的策略聯盟，這些聯盟正在打造從診斷到長期管理的一體化解決方案。

為高階主管提供實用建議，以協調臨床創新、供應鏈韌性和商業策略，從而實現更好的腎臟護理和永續的組織競爭力。

產業領導者必須採取積極主動的方式，兼顧臨床影響、營運韌性和商業性可行性。首先，策略性地優先發展整合式醫療路徑，將診斷、治療、監測和透析服務連結起來，將有助於醫療服務提供者和製造商展現更佳的治療效果和成本效益。其次，供應鏈多元化和靈活的採購合約可以降低貿易政策波動和零件短缺帶來的風險。應結合基於情境的庫存規劃來評估近岸外包和多源採購策略。

透明且有系統的研究途徑，結合對關鍵相關人員的訪談、對二手文獻的系統性檢驗以及基於情境的三角測量，可以得出可靠的策略結論。

本分析所依據的研究將一手定性研究結果與嚴謹的二手資料檢驗相結合，從而得出可靠且可操作的結論。主要研究方法包括對臨床醫生、採購經理、透析中心管理人員和行業高管進行結構化訪談，以了解實際的限制因素和推動技術應用的因素。除了這些相關人員的觀點外，對監管公告、更新的臨床指南和同行評審文獻的仔細審查，也為臨床趨勢和證據要求提供了背景資訊。

一份簡潔、前瞻性和綜合性的分析報告強調，需要製定一個具有韌性、綜合性和以本地為基礎的策略，以改善整個腎臟護理過程的結果。

總之，慢性腎臟病治療正處於轉折點，診斷、透析技術、藥物和數位化監測等方面的進步融合，有望顯著改善患者預後並提高系統效率。然而，要充分發揮這一潛力，需要製定一項綜合策略，以因應不同領域的需求、區域差異和供應鏈的脆弱性。積極主動地將臨床證據的產生與營運計劃以及與保險公司的合作相結合的相關人員，將更有能力將創新轉化為可規模化的影響。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：慢性腎臟病市場（依治療方法分類）

  • 診斷
    • 診斷影像
    • 臨床檢測
  • 透析
    • 血液透析
    • 腹膜透析
  • 製藥
    • 抗高血壓藥物
    • 紅血球生成素促效劑
      • Darbepoetinα
      • 促紅素α
    • 鐵補充劑
    • 磷粘合劑
  • 移植

第9章：依疾病進展階段慢性腎臟病市場

  • 初期
  • 末期腎病
  • 中度疾病
  • 嚴重

第10章：慢性腎臟病市場：依最終用戶分類

  • 門診部
  • 透析中心
  • 居家照護
  • 醫院

第11章慢性腎臟病市場：依產品分類

  • 消耗品
    • 導管和針頭
    • 過濾透析器
  • 裝置
    • 血液透析機
    • 腹膜透析週期計
  • 監控設備
    • 血液檢測設備
    • 醫學影像系統

第12章 依病患類型分類的慢性腎臟病市場

  • 成人版
  • 兒童

第13章慢性腎臟病市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章慢性腎臟病市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章慢性腎臟病市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國慢性腎臟病市場

第17章：中國慢性腎臟病市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Allmed Medical Products Co., Ltd.
  • AngioDynamics, Inc.
  • Apotex Inc.
  • Asahi Kasei Corporation
  • AstraZeneca PLC
  • B. Braun SE
  • Baxter International, Inc.
  • Becton, Dickinson and Company
  • Centessa Pharmaceuticals Limited
  • DaVita Inc.
  • Dialife SA
  • Dr. Reddys Laboratories Ltd.
  • Evoqua Water Technologies LLC
  • Fresenius Medical Care AG
  • Galapagos NV
  • Hemoclean Co. Ltd.
  • JMS Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Medtronic PLC
  • Merck & Co., Inc.
  • Nikkiso Co., Ltd.
  • Nipro Corporation
  • Novartis AG
  • NxStage Medical Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals Inc.
  • Rockwell Medical Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Toray Medical Co., Ltd.
  • Trivitron Healthcare
  • XORTX Therapeutics Inc.
Product Code: MRR-99555D550528

The Chronic Kidney Disease Market was valued at USD 145.75 billion in 2025 and is projected to grow to USD 154.70 billion in 2026, with a CAGR of 6.70%, reaching USD 229.64 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 145.75 billion
Estimated Year [2026] USD 154.70 billion
Forecast Year [2032] USD 229.64 billion
CAGR (%) 6.70%

A compelling and authoritative overview positioning chronic kidney disease as an urgent multisectoral clinical and operational priority demanding coordinated strategic responses

Chronic kidney disease represents a multifaceted and growing challenge at the intersection of clinical care, health systems resilience, and population health management. The condition imposes sustained demands on diagnostic pathways, long-term therapeutics, dialysis infrastructure, and transplantation networks, while intersecting with comorbidities such as diabetes and cardiovascular disease. Consequently, stakeholders from device manufacturers and pharmaceutical developers to providers and payers must navigate evolving clinical standards, regulatory expectations, and shifting patient-care models.

Moving from isolated clinical encounters to integrated care delivery requires clarity about where the greatest friction points lie. Early detection through laboratory and imaging diagnostics can change trajectories, yet barriers to access and care coordination persist. In parallel, innovations in dialysis technology and transplant medicine are improving outcomes, though they compel systems-level planning for capacity and reimbursement. Taken together, these dynamics create both risk and opportunity: risk in the form of constrained access and rising costs for vulnerable populations, and opportunity in the form of innovation that can reduce morbidity and enable more efficient use of resources.

For decision-makers, the imperative is clear. Strategic investments that prioritize diagnostic accuracy, scalable dialysis modalities, pharmacologic optimization, and integrated care pathways will determine which organizations can deliver superior outcomes while managing total cost of care. This report frames that imperative by synthesizing clinical trends, operational pressures, and technological shifts to guide evidence-based decisions.

An incisive analysis of the major clinical, technological, and business model shifts reshaping chronic kidney disease care across diagnostics, therapeutics, and care delivery

The landscape of chronic kidney disease care is undergoing transformative shifts driven by technological innovation, care delivery redesign, and evolving regulatory attention. Advances in diagnostic precision are enabling earlier detection and risk stratification, while digital health platforms and remote monitoring are extending clinical oversight beyond traditional inpatient and clinic settings. At the same time, dialysis modalities are diversifying: improvements in hemodialysis hardware and peritoneal dialysis cyclers are complemented by smarter consumables and monitoring devices that support personalized treatment regimens.

These clinical and technological changes are also reshaping business models. Manufacturers are increasingly bundling devices with software services to create recurring revenue streams and improve patient adherence. Health systems are experimenting with home-based care and hybrid ambulatory models to reduce hospital dependence and enhance patient quality of life. Moreover, pharmaceutical management of anemia, mineral bone disorder, and blood pressure control is becoming more nuanced as novel agents and biosimilars enter clinical practice, necessitating updated formularies and clinical pathways.

As a result, organizations that integrate diagnostics, therapeutics, and digital monitoring into cohesive care pathways will be better positioned to improve outcomes and operational efficiency. Conversely, stakeholders that remain siloed risk falling behind as reimbursement and regulatory frameworks begin to favor integrated, value-oriented solutions. Understanding these shifts is essential for aligning investment, R&D, and clinical strategies with the future of kidney care.

A practical examination of how recent tariff policies reshape supply chain resilience, procurement strategies, and patient access across kidney care delivery systems in 2025

The introduction of targeted tariffs affecting medical technology and pharmaceutical imports has created ripple effects across supply chains, procurement strategies, and cost structures within the chronic kidney disease ecosystem. Tariff changes can alter the relative competitiveness of imported dialysis hardware, consumables, and certain active pharmaceutical ingredients versus domestically produced alternatives. In turn, providers and integrated delivery networks reassess procurement contracts, inventory strategies, and supplier diversification to ensure continuity of care for dialysis-dependent and transplant-reliant patients.

Operationally, higher import costs for capital equipment and consumables can accelerate conversations around asset utilization and lifecycle management. Facilities may extend equipment service lives, prioritize high-throughput modalities, or shift toward modular solutions that reduce dependence on high-cost imported components. Parallel to these operational responses, some manufacturers and contract manufacturers are exploring nearshoring and reconfigured manufacturing footprints to mitigate tariff exposure and shorten lead times. These moves can improve supply resilience but also require capital investment and regulatory alignment.

From a patient access perspective, tariffs can have indirect effects by affecting the cost base of care delivery and the timing of technology adoption. Payers and policy makers may respond through adjusted reimbursement policies, strategic subsidies, or procurement consortia designed to preserve access to essential therapies. Consequently, stakeholders should assess tariff-related scenarios proactively, incorporating supply chain risk modeling into procurement decisions, negotiating flexible purchase terms, and engaging with policymakers to ensure continuity of patient-centered services.

Detailed segmentation-driven insights revealing how therapy modalities, disease stages, care settings, product classes, and patient demographics determine clinical priorities and commercial strategies

Understanding the market requires a granular view across therapy types, disease stages, end users, product classes, and patient demographics, because each segmentation dimension drives distinct clinical and commercial dynamics. Based on therapy type, care pathways range from Diagnostics, which includes Imaging Diagnostics and Laboratory Diagnostics, to Dialysis, encompassing Hemodialysis and Peritoneal Dialysis, Pharmaceuticals comprising Antihypertensives, Erythropoietin Stimulating Agents such as Darbepoetin Alfa and Epoetin Alfa, Iron Supplements, and Phosphate Binders, and finally Transplantation with its own pre- and post-operative management needs. Each of these therapy domains generates unique evidence requirements, regulatory considerations, and procurement cycles.

Based on disease stage, the needs of patients differ markedly across Early Disease, Moderate Disease, Severe Disease, and End Stage Renal Disease, shaping diagnostic intensity, therapeutic regimens, and the urgency of access to dialysis or transplant services. Based on end user, care settings span Ambulatory Care Clinics, Dialysis Centers, Home Care environments, and Hospitals, each of which imposes distinct operational constraints, staffing models, and capital planning horizons. Based on product, clinical and purchasing decisions differentiate Consumables such as Catheters & Needles and Filters & Dialyzers, Equipment including Hemodialysis Machines and Peritoneal Dialysis Cyclers, and Monitoring Devices like Blood Testing Devices and Imaging Systems, thereby influencing vendor relationships and after-sales service models. Finally, based on patient type, Adult and Pediatric populations present different clinical protocols, device sizing requirements, and psychosocial support needs, which in turn inform specialized product development and care pathways.

Taken together, these segmentation lenses reveal that integrated strategies must be tailored: diagnostic innovations may yield greatest benefit in early stages, home-based dialysis growth hinges on device portability and consumable supply chains, pharmaceutical portfolio management requires alignment with stage-specific comorbidity profiles, and pediatric care demands dedicated attention to device design and family-centered delivery models. Consequently, stakeholders should design interventions with segmentation specificity, aligning R&D, regulatory planning, and commercial deployment to the clinical realities of each cohort and care setting.

A regionally nuanced analysis of how geopolitical, regulatory, and health system differences shape chronic kidney disease care priorities across major global regions

Regional dynamics exert powerful influence on how chronic kidney disease care is organized, financed, and delivered, and they shape strategic priorities for manufacturers, providers, and payers. In the Americas, health systems emphasize scale, centralized dialysis networks, and a growing interest in home-based modalities, alongside payer-driven efforts to control downstream costs through bundled payments and value-based care pilots. Regulatory pathways and reimbursement designs in this region influence adoption timelines for innovative devices and pharmaceuticals, and supply chain considerations often prioritize domestically compliant manufacturing or long-term distributor relationships.

In Europe, Middle East & Africa, a mosaic of regulatory regimes and funding mechanisms creates heterogenous adoption patterns. Western European systems tend to prioritize evidence-driven reimbursement and integrated care pathways, while parts of the Middle East and Africa face capacity constraints that elevate the importance of scalable, low-resource dialysis solutions and targeted training programs. Cross-border procurement, public-private partnerships, and donor-funded initiatives also play meaningful roles in expanding access.

In Asia-Pacific, rapid demographic change combined with a rising burden of chronic diseases has led to substantial investments in diagnostics, expanded dialysis capacity, and growing uptake of home therapies where feasible. Supply chain diversification is particularly salient in this region, with a mix of domestic manufacturing and international partnerships shaping product availability. Overall, regional strategies must balance clinical efficacy, affordability, and logistical feasibility, and organizations that tailor offerings to these geopolitical nuances will achieve stronger adoption and sustainable impact.

Actionable competitive intelligence highlighting how R&D investment, strategic partnerships, and service excellence are reshaping leadership across kidney care product and solution markets

Competitive dynamics in the chronic kidney disease arena are defined by a combination of technological capability, manufacturing scale, regulatory expertise, and strategic partnerships. Leading firms invest heavily in R&D for next-generation dialysis equipment, consumables that improve patient comfort and outcomes, and monitoring devices that enable remote patient management. Equally important are strategic alliances between device makers, pharmaceutical companies, and digital health providers that create integrated solutions spanning diagnostics to long-term management.

Additionally, contract manufacturing and supply chain partners are gaining prominence as companies seek to de-risk production and accelerate time to market. Firms that build robust post-market surveillance and service networks secure greater trust among providers, while those that offer data-enabled service models can demonstrate value through reduced hospitalizations and improved treatment adherence. M&A and equity partnerships continue to be tools for accelerating entry into new geographies or therapeutic niches, particularly where regulatory complexity or localized manufacturing capacity presents a barrier to rapid expansion.

Finally, a growing cohort of innovative entrants specializing in digital therapeutics, remote monitoring, and patient engagement is reshaping expectations around continuous care. Established companies that adopt open innovation models and invest in interoperability will be better positioned to capture long-term customer relationships and to deliver holistic care solutions that meet evolving payer and provider demands.

High-impact practical recommendations for executives to align clinical innovation, supply resilience, and commercial strategies to deliver better kidney care and sustained organizational advantage

Industry leaders must adopt a proactive stance that aligns clinical impact with operational resilience and commercial viability. First, strategic prioritization of integrated care pathways-linking diagnostics, therapeutics, monitoring, and dialysis services-will enable providers and manufacturers to demonstrate improved outcomes and cost efficiencies. Second, supply chain diversification and flexible procurement contracting will mitigate exposure to trade policy fluctuations and component shortages; nearshoring and multi-sourcing strategies should be evaluated alongside scenario-based inventory planning.

Third, investment in home-based care infrastructure and scalable remote monitoring platforms will expand access while improving patient experience, but success requires coordinated training, reimbursement engagement, and device suitability for diverse home environments. Fourth, pharmaceutical strategy should emphasize formulary alignment, real-world evidence generation, and collaboration with clinicians to optimize anemia and mineral bone disorder management across disease stages. Fifth, companies should build service-oriented business models that combine equipment, consumables, and data services to create recurring revenue and strengthen customer retention.

Finally, leaders must engage proactively with policymakers and payers to shape reimbursement frameworks that reward integrated, patient-centered care. By aligning clinical evidence generation with regulatory and payer requirements, organizations can accelerate adoption and secure sustainable pathways for scalable innovation. These combined actions will support resilient growth while improving outcomes for patients living with chronic kidney disease.

A transparent and methodical research approach combining primary stakeholder interviews, systematic secondary literature review, and scenario-based triangulation to support robust strategic conclusions

The research underpinning this analysis synthesizes primary qualitative insights and rigorous secondary data triangulation to ensure robust, actionable conclusions. Primary methods included structured interviews with clinicians, procurement leaders, dialysis center administrators, and industry executives to capture real-world operational constraints and adoption drivers. These stakeholder perspectives were complemented by an examination of regulatory communications, clinical guideline updates, and peer-reviewed literature to contextualize clinical trends and evidence requirements.

Secondary research encompassed systematic reviews of technical literature on dialysis technologies, pharmaceutical therapeutic classes, and diagnostic methodologies, combined with supplier and manufacturing landscape analysis to assess supply chain dependencies. Data triangulation techniques were applied to reconcile disparate sources and to surface consistent themes across geographies and care settings. Scenario analysis was used to explore the implications of supply chain disruptions and tariff changes, while sensitivity checks ensured that strategic recommendations remained robust under varying operational assumptions.

Throughout the process, emphasis was placed on transparency of assumptions and on documenting evidence hierarchies so that readers can trace conclusions to source material and stakeholder testimony. This methodology supports confident decision-making by blending frontline insights with documented clinical and operational evidence.

A concise and forward-looking synthesis underscoring the imperative for integrated, regionally tailored, and resilient strategies to improve outcomes across kidney care pathways

In closing, chronic kidney disease care is at an inflection point where advances in diagnostics, dialysis technology, pharmaceuticals, and digital monitoring can converge to produce meaningful gains in patient outcomes and system efficiency. However, realizing that potential will require integrated strategies that address segmentation-specific needs, regional nuances, and supply chain vulnerabilities. Stakeholders who proactively align clinical evidence generation with operational planning and payer engagement will be best positioned to translate innovation into scalable impact.

The path forward calls for cross-sector collaboration: manufacturers, providers, payers, and policymakers must work together to create reimbursement structures that reward integrated care, invest in workforce training for home-based and ambulatory models, and prioritize supply chain resilience to protect access to essential therapies. When these elements are aligned, the health system can deliver better quality of life for patients, optimize resource utilization, and foster sustainable innovation. This synthesis offers a strategic framework to guide next steps and to inform investments that will shape the future of kidney care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Kidney Disease Market, by Therapy Type

  • 8.1. Diagnostics
    • 8.1.1. Imaging Diagnostics
    • 8.1.2. Laboratory Diagnostics
  • 8.2. Dialysis
    • 8.2.1. Hemodialysis
    • 8.2.2. Peritoneal Dialysis
  • 8.3. Pharmaceuticals
    • 8.3.1. Antihypertensives
    • 8.3.2. Erythropoietin Stimulating Agents
      • 8.3.2.1. Darbepoetin Alfa
      • 8.3.2.2. Epoetin Alfa
    • 8.3.3. Iron Supplements
    • 8.3.4. Phosphate Binders
  • 8.4. Transplantation

9. Chronic Kidney Disease Market, by Disease Stage

  • 9.1. Early Disease
  • 9.2. End Stage Renal Disease
  • 9.3. Moderate Disease
  • 9.4. Severe Disease

10. Chronic Kidney Disease Market, by End User

  • 10.1. Ambulatory Care Clinic
  • 10.2. Dialysis Center
  • 10.3. Home Care
  • 10.4. Hospital

11. Chronic Kidney Disease Market, by Product

  • 11.1. Consumables
    • 11.1.1. Catheters & Needles
    • 11.1.2. Filters & Dialyzers
  • 11.2. Equipment
    • 11.2.1. Hemodialysis Machine
    • 11.2.2. Peritoneal Dialysis Cycler
  • 11.3. Monitoring Devices
    • 11.3.1. Blood Testing Devices
    • 11.3.2. Imaging Systems

12. Chronic Kidney Disease Market, by Patient Type

  • 12.1. Adult
  • 12.2. Pediatric

13. Chronic Kidney Disease Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Chronic Kidney Disease Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Chronic Kidney Disease Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Chronic Kidney Disease Market

17. China Chronic Kidney Disease Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Allmed Medical Products Co., Ltd.
  • 18.7. AngioDynamics, Inc.
  • 18.8. Apotex Inc.
  • 18.9. Asahi Kasei Corporation
  • 18.10. AstraZeneca PLC
  • 18.11. B. Braun SE
  • 18.12. Baxter International, Inc.
  • 18.13. Becton, Dickinson and Company
  • 18.14. Centessa Pharmaceuticals Limited
  • 18.15. DaVita Inc.
  • 18.16. Dialife SA
  • 18.17. Dr. Reddys Laboratories Ltd.
  • 18.18. Evoqua Water Technologies LLC
  • 18.19. Fresenius Medical Care AG
  • 18.20. Galapagos NV
  • 18.21. Hemoclean Co. Ltd.
  • 18.22. JMS Co., Ltd.
  • 18.23. Johnson & Johnson Services, Inc.
  • 18.24. Medtronic PLC
  • 18.25. Merck & Co., Inc.
  • 18.26. Nikkiso Co., Ltd.
  • 18.27. Nipro Corporation
  • 18.28. Novartis AG
  • 18.29. NxStage Medical Inc.
  • 18.30. Otsuka Pharmaceutical Co., Ltd.
  • 18.31. Reata Pharmaceuticals Inc.
  • 18.32. Rockwell Medical Inc.
  • 18.33. Sanofi S.A.
  • 18.34. Teva Pharmaceutical Industries Ltd.
  • 18.35. Toray Medical Co., Ltd.
  • 18.36. Trivitron Healthcare
  • 18.37. XORTX Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC KIDNEY DISEASE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHRONIC KIDNEY DISEASE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ANTIHYPERTENSIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ANTIHYPERTENSIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DARBEPOETIN ALFA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DARBEPOETIN ALFA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EPOETIN ALFA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EPOETIN ALFA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EPOETIN ALFA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IRON SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IRON SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IRON SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHOSPHATE BINDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHOSPHATE BINDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHOSPHATE BINDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EARLY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EARLY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EARLY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END STAGE RENAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END STAGE RENAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END STAGE RENAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MODERATE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MODERATE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MODERATE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SEVERE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SEVERE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SEVERE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY AMBULATORY CARE CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY AMBULATORY CARE CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY AMBULATORY CARE CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CATHETERS & NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CATHETERS & NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CATHETERS & NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY FILTERS & DIALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY FILTERS & DIALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY FILTERS & DIALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS MACHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS MACHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS MACHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS CYCLER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS CYCLER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS CYCLER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BLOOD TESTING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BLOOD TESTING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BLOOD TESTING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 235. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 239. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 241. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 242. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 243. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 244. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 274. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 275. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 276. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 278. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 280. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 281. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 282. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 283. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 287. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 288. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 291. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 293. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 294. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 295. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 296. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA CHRONIC KIDNEY DISEASE MARKET